Processa Historical Income Statement
| PCSA Stock | USD 1.33 0.08 6.40% |
Historical analysis of Processa Pharmaceuticals income statement accounts such as Research Development of 6.1 M, Cost Of Revenue of 211, Total Operating Expenses of 12 M or Depreciation And Amortization of 211 can show how well Processa Pharmaceuticals performed in making a profits. Evaluating Processa Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Processa Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Processa Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Processa Pharmaceuticals is a good buy for the upcoming year.
Processa |
About Processa Income Statement Analysis
Processa Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Processa Pharmaceuticals shareholders. The income statement also shows Processa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Processa Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Processa Pharmaceuticals. It is also known as Processa Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Processa Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Processa Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Processa Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Processa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.At present, Processa Pharmaceuticals' Interest Expense is projected to decrease significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 5.9 M, whereas Gross Profit is forecasted to decline to (233.10).
Processa Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Processa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Processa Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 36.7K | 281.1K | 362.0 | 101.2K | 91.1K | 115.6K | |
| Selling General Administrative | 1.6M | 3.3M | 4.7M | 8.8M | 5.7M | 5.9M | |
| Gross Profit | (877.9K) | (15.1M) | (12.1M) | (27.5M) | (222.0) | (233.1) | |
| Other Operating Expenses | 3.9M | 6.4M | 11.6M | 20.3M | 11.5M | 12.0M | |
| Operating Income | (3.9M) | (15.1M) | (12.1M) | (27.5M) | (11.5M) | (10.9M) | |
| Ebit | (3.9M) | (6.5M) | (12.0M) | (20.3M) | (11.5M) | (10.9M) | |
| Research Development | 2.3M | 3.2M | 6.9M | 11.5M | 5.8M | 6.1M | |
| Ebitda | (3.1M) | (5.6M) | (11.1M) | (19.5M) | (11.5M) | (10.9M) | |
| Cost Of Revenue | 877.9K | 15.1M | 12.1M | 27.5M | 222.0 | 210.9 | |
| Total Operating Expenses | 3.9M | 6.4M | 11.6M | 20.3M | 11.5M | 12.0M | |
| Income Before Tax | (4.0M) | (15.4M) | (12.0M) | (27.4M) | (11.1M) | (10.6M) | |
| Net Income | (3.4M) | (14.4M) | (11.4M) | (54.8M) | (11.1M) | (11.7M) | |
| Depreciation And Amortization | 815.3K | 882.1K | 875.3K | 874.0K | 222.0 | 210.9 | |
| Total Other Income Expense Net | (25.1K) | (277.9K) | 175.4K | 101.2K | 335.5K | 352.3K | |
| Income Tax Expense | (602.7K) | (1.0M) | (530.6K) | 27.4M | (2.0) | (1.9) | |
| Net Income From Continuing Ops | (3.4M) | (14.4M) | (11.4M) | (27.4M) | (21.7M) | (20.6M) | |
| Net Income Applicable To Common Shares | (3.8M) | (3.9M) | (19.0M) | (11.4M) | (10.3M) | (9.8M) | |
| Net Interest Income | (25.1K) | (277.9K) | 11.6K | 101.2K | 326.6K | 342.9K | |
| Interest Income | 11.5K | 3.2K | 12.0K | 101.2K | 326.6K | 342.9K | |
| Reconciled Depreciation | 803.8K | 803.8K | 791.0K | 788.5K | 197.2K | 187.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.